RAPISCAN

New indication.

Favourable opinion for reimbursement for diagnostic use as a pharmacological stress agent during the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated.

What therapeutic improvement?

No clinical added value in the diagnostic strategy for FFR measurement including adenosine used off-label.

Role in the diagnostic pathway?

The patients concerned by FFR measurement are only those suspected of having stable coronary-artery disease in the event of multi-vessel or intermediate lesions for which previous investigations have not provided useful information or could not be performed.

To induce hyperaemia in the patient in the context of measurement of FFR, although it does not have an MA in this indication, adenosine is the reference product for this investigation, recommended by the European Society of Cardiology when non-invasive methods are contraindicated, not available or do not enable a diagnosis to be reached.

Role of the medicinal product in the care pathway

RAPISCAN (regadenoson) is a diagnostic option in the same way as products containing adenosine (although off-label) for diagnostic use as a pharmacological stress agent during the measurement of fractional flow reserve (FFR) of a single coronary artery stenosis during invasive coronary angiography, when repeated FFR measurements are not anticipated.